Parallel Chemistry and Compound Libraries
Compound libraries for successful drug discovery projects
The quality of compound libraries and screening compounds affect the fate of a drug discovery project – Taros’ compound library designs target underpopulated druglike chemical space. High quality compound libraries requires chemical creativity and profound high throughput synthesis knowledge to achieve the highest possible molecular diversity. Our efficient production process reduces the costs per compound by utilising parallel synthesis and high throughput purification. Taros has established a highly successful and efficient compound library and parallel chemistry group as evidenced by our outstanding contribution to the European Lead Factory (ELF), for which we successfully designed, synthesized and delivered over 40,000 screening compounds from more than 100 chemical scaffolds. Moreover, in our role as an ELF executive member and head of the chemistry consortium, Taros was responsible for managing the entire chemistry consortium (7 companies and 10 academic groups throughout Europe) to develop and produce the ELF public compound collection consisting of 200.000 novel and lead-like screening compounds.
Our high throughput chemistry services include:
- Screening libraries
- Fragment collection
- Focused and targeted libraries
- Hit and SAR expansion arrays
- Remarkably lower clogP
- Novel screening compounds to access druglike chemical space
- High-throughput synthesis by parallel chemistry
- High-throughput synthesis by parallel chemistry
Druglike physicochemical properties and medicinal chemistry relevance
Taros unlocks underexplored chemical space by encoding natural product derived topology into novel scaffolds. Our library designs show a remarkably lower clogP, an increased number of chiral atoms and a significantly higher fraction of sp3-hybridised carbons (fsp3). In contrast to commercially available screening libraries, the high 3D character is engineered into the scaffolds and does not solely derive from a favourable decoration at its periphery. Involving our experienced medicinal chemists guarantees that our scaffolds are decorated with chemical building blocks that are of medicinal chemistry relevance. In addition, our scaffolds bear a high number of diversity points for systematic exploration of the chemical space around the design and hence rapid lead identification.
- Optimal sampling of chemical space by cheminformatics
- Creativity in the design and the reduction to practice
- Translation of known methods to novel scaffolds
- Development of new routes to hitherto inaccessible scaffolds
- Wide range of reactions established for parallel synthesis
- Awareness of possibilities AND limitations
- Broad experience in high throughput chemistry
- Dedicated group for parallel chemistry & compound library design
ELF30K Library Property Distributions
Scaffold Diversity Analysis
Check out our Medicinal Chemistry
Or maybe interested in other areas?
Custom Synthesis
Indications and Gene Families
Looks interesting?
As a leading CRO in Europe, Taros provides comprehensive drug discovery chemistry services for large Pharma and Biotech corporations as well as for Research Institutes and Academia
Frequently Asked Questions
Taros designs and synthesises screening libraries, fragment collections, focused and targeted libraries, and hit or SAR-expansion arrays. Parallel synthesis and high-throughput purification are used to produce related compounds efficiently while reducing the cost per compound and accelerating the exploration of chemical space.
Taros targets underexplored, drug-like chemical space by incorporating natural-product-inspired topology, three-dimensional scaffolds, increased sp³ character, chiral centres and multiple diversity points. Cheminformatics and medicinal chemistry expertise are used to select scaffolds and building blocks with suitable physicochemical properties and relevance to drug discovery.
For the European Lead Factory, Taros designed, synthesised and delivered more than 40,000 screening compounds from over 100 chemical scaffolds. As an executive member and head of the chemistry consortium, Taros also coordinated seven companies and ten academic groups contributing to a public collection of 200,000 novel, lead-like compounds.